New hope for Crohn's scarring: risankizumab vs ustekinumab in major trial
NCT ID NCT07177118
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial will test two drugs, risankizumab and ustekinumab, in 260 adults with fibrostenotic Crohn's disease—a form where the bowel becomes scarred and narrow. The study compares how well each drug prevents further scarring over three years. Participants will receive either drug by IV and then injections. The goal is to see if these IL-23 inhibitors can slow disease progression and improve symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- risankizumab and ustekinumab (IL-23 inhibitors)
- What this could lead to
- If successful, this could offer a new treatment option for people with fibrostenotic Crohn's disease, potentially slowing or preventing bowel scarring.
- What could go wrong
- This is an early-stage Phase 3 trial that hasn't started recruiting yet. It's open-label, so both patients and doctors know which drug is given, which can bias results. The drugs may not work for all patients or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?